Lifecycle Management and Strategic Alliances
First written in FY2016. 20 of 40 entries say "Restated". Latest entry: 2026-10-09.
The whole theme swung hardest in 2022: 1 of 12 companies on the "Worse" side.
5 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In December 2025, we signed an agreement with Canada’s Duchesnay Inc. concerning the development and sale in Japan of Bonjesta, a treatment for nausea and vomiting during pregnancy, commonly known as morning sickness. In March 2026, we signed an agreement with South Korea’s LG Chem, Ltd. concerning sales in South Korea and Thailand of dienogest, which we sell in Japan for indications including endometriosis.」
The domestic rollout of in-licensed products and the overseas expansion of proprietary products were specifically advanced through strategic alliances. - FY2026-H1AdvancedAnnual report
「On 22 September 2025, we entered into an agreement concerning the underwriting of a third-party allotment of shares by アンドファーマ株式会社 and the acquisition of shares in アンドファーマ株式会社 by acquiring part of the shares held by 合同会社ジェイ・イー・エイチ. As a result, we acquired a 20% stake in アンドファーマ株式会社 effective 1 October 2025 and made the company an equity-method associate.」
Specific progress is described in partnerships with external companies through new share acquisitions and the application of the equity method, including the signing of agreements and the acquisition of 20%. - FY2025AdvancedAnnual report
「In August 2024, we signed an agreement with Meiji Seika Pharma Co., Ltd. concerning sales of “Epadel” in the ASEAN region and Taiwan. In December 2024, we signed an agreement with Korea’s Kuhnil Pharm. Co., Ltd. concerning sales of “Epadel” in South Korea.」
Specific progress in the overseas expansion of Epadel through strategic alliances is described, including the signing of sales agreements in ASEAN, Taiwan and South Korea. - FY2025-H1RestatedAnnual report
「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」
We continue to pursue a policy of actively promoting research and development partnerships with companies in Japan and overseas. No decisions were made or agreements entered into concerning material contracts or similar matters during the six-month period ended September 2024. - FY2024AdvancedAnnual report
「In addition, in October 2023, we entered into a marketing partnership agreement with Shionogi & Co.,Ltd. for ACT-541468 in Japan. In March 2024, we also entered into an agreement with Meiji Seika Pharma Co., Ltd. concerning the marketing of MND-21 in China.」
Specific agreements concerning ACT-541468 and MND-21 are described with respect to alliances in research and development and sales. - FY2024-Q3AdvancedAnnual report
「The following important sales agreement was newly executed during the third quarter of the fiscal year. Counterparty: Shionogi & Co., Ltd. Country: Japan Contract: Supply and exclusive distribution of the insomnia treatment “ACT-541468” Contract year: 2023」
A supply and exclusive sales agreement was signed with Shionogi & Co.,Ltd. for the insomnia treatment “ACT-541468,” representing specific progress in the strategic alliance. - FY2024-Q2RestatedAnnual report
「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」
The policy of actively promoting research and development partnerships with companies in Japan and overseas is reaffirmed. No important contracts or similar agreements were decided on or signed during the second quarter of the consolidated fiscal year. - FY2024-Q1Termination of an individual partnership agreementAnnual report
「Pfizer Inc. Japan Joint development, importation and joint sales of the antidepressant “MD-120” 2019」
The agreement with Pfizer Inc. for the joint development, importation and joint sales of MD-120 is listed as an important contract that ended during the first quarter of the consolidated fiscal year. - FY2023AdvancedAnnual report
「In January 2023, we signed a business partnership agreement with PuREC Co., Ltd. concerning development of the manufacturing process for high-purity mesenchymal stem cell REC and related activities. In March 2023, we signed a joint commercialization agreement with Human Life Code Co., Ltd. for “HLC-001,” a cell therapy product derived from umbilical cord tissue.」
With respect to regenerative medicine products, specific business partnership and joint commercialization agreements were signed in January and March 2023. - FY2023-Q3AdvancedAnnual report
「As part of its licensing activities, the company entered into agreements in December 2022 with Ferring Pharmaceuticals Co., Ltd. and Eli Lilly Japan K.K., respectively, for therapeutic products indicated for ulcerative colitis.」
With respect to the policy of pursuing research and development and sales partnerships with companies in Japan and overseas, specific licensing agreements signed with Ferring Pharmaceuticals and Eli Lilly Japan are described. - FY2023-Q2RestatedAnnual report
「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」
The policy of conducting research and development activities through research and development partnerships with companies in Japan and overseas is reaffirmed. - FY2023-Q1RestatedAnnual report
「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」
The policy of actively promoting research and development partnerships with companies in Japan and overseas is reaffirmed. No new partnership agreements were decided on or signed. - FY2022AdvancedAnnual report
「“Realda” for pediatric use, “Lexapro” for pediatric use, the antidepressant “MD-120,” which is being jointly developed with Pfizer Inc., the treatment for hypertriglyceridemia “MND-21,” whose development is being pursued in partnership with Sumitomo Pharma (Suzhou) in China, and the insomnia treatment “ACT-541468,” which is being jointly developed with Idorsia Pharmaceuticals Japan Ltd., are in Phase III clinical development.」
A specific development is described: multiple products jointly developed with partners are in Phase III clinical development. - FY2022-Q3RestatedAnnual report
「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」
The policy of actively promoting research and development partnerships with companies in Japan and overseas is reaffirmed. No important contracts or similar agreements were decided on or signed during the third quarter of the consolidated fiscal year. - FY2022-Q2RestatedAnnual report
「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」
The policy of actively promoting research and development partnerships with companies in Japan and overseas is reaffirmed. It is stated that no important contracts or similar agreements were decided on or signed during the second quarter of the consolidated fiscal year. - FY2022-Q1RestatedAnnual report
「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」
The policy of actively promoting research and development partnerships with companies in Japan and overseas is reaffirmed. It is stated that no important contracts or similar agreements were decided on or signed during the first quarter of the consolidated fiscal year. - FY2021AdvancedAnnual report
「For “Epadel,” the overseas subsidiary of the partner obtained import and marketing approval in Thailand in October 2020 for the indication of hypertriglyceridemia and began sales in April 2021. In Vietnam, the partner’s affiliated partner applied for import and marketing approval.」
Specific progress in an alliance for overseas expansion is described, including obtaining approval and starting sales in Thailand and filing an application for approval in Vietnam. - FY2021-Q3RestatedAnnual report
「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」
The policy of actively promoting research and development partnerships with companies in Japan and overseas is reaffirmed. It is stated that no important management-related contracts or similar agreements were decided on or signed during the third quarter of the consolidated fiscal year. - FY2021-Q2RestatedAnnual report
「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」
The policy of actively promoting research and development partnerships with companies in Japan and overseas is reaffirmed. It is stated that no important management-related contracts or similar agreements were decided on or signed during the second quarter of the consolidated fiscal year. - FY2021-Q1RestatedAnnual report
「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」
The policy of actively promoting research and development partnerships with companies in Japan and overseas is reaffirmed. It is stated that no important contracts or similar agreements were decided on or signed during the first quarter of the consolidated fiscal year. - FY2020AdvancedAnnual report
「During the consolidated fiscal year, we advanced and expanded items in the development pipeline, focused on new drugs including “Realda,” “Goofice,” “Movicol” and “Lexapro,” and promoted the overseas expansion of the “high-purity EPA formulation,” while continuing to invest in research and development and other activities for the future.」
It is stated that progress and expansion of the development pipeline, a focus on new drugs, and the overseas expansion of the high-purity EPA formulation were pursued. - FY2020-Q3RestatedAnnual report
「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」
The policy of actively promoting research and development partnerships with companies in Japan and overseas is reaffirmed. It is stated that no important management-related contracts or similar agreements were decided on or signed during the third quarter of the consolidated fiscal year. - FY2020-Q2RestatedAnnual report
「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」
The policy of actively promoting research and development partnerships with companies in Japan and overseas is reaffirmed. It is stated that no important management-related contracts or similar agreements were decided on or signed during the second quarter of the consolidated fiscal year. - FY2020-Q1AdvancedAnnual report
「During the first three months of the fiscal year, the company entered into a memorandum of understanding with Mitsubishi Tanabe Pharma Corporation regarding an extension of the term and other matters under the agreement for the co-promotion of the antidepressant “Lexapro.”」
A memorandum of understanding covering an extension of the term and other matters was signed for the joint sales agreement for Lexapro, representing specific progress in the existing strategic partnership. - FY2019AdvancedAnnual report
「The pediatric indication for “Lexapro” and the antidepressant “desvenlafaxine (generic name),” for which the company entered into an agreement with Pfizer Inc. in March 2019 covering development, sales and other matters, are each in Phase III clinical development.」
A specific development in the strategic alliance is described: an agreement was signed with Pfizer Inc. concerning the development, sale and other activities related to desvenlafaxine. - FY2019-Q3RestatedAnnual report
「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」
The policy of actively promoting research and development partnerships with companies in Japan and overseas is reaffirmed. It is stated that no important management-related contracts or similar agreements were decided on or signed during the third quarter of the consolidated fiscal year. - FY2019-Q2RestatedAnnual report
「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」
The policy of actively promoting research and development partnerships with companies in Japan and overseas is reaffirmed. It is stated that no important management-related contracts or similar agreements were decided on or signed during the second quarter of the consolidated fiscal year. - FY2019-Q1AdvancedAnnual report
「In June 2018, the company entered into an agreement with Amarin Corporation for the development and commercialization of a novel high-purity EPA formulation in the United States and other regions.」
A specific development in the alliance program is described: a development and commercialization agreement was signed with Amarin Corporation for a new high-purity EPA formulation. - FY2018AdvancedAnnual report
「During the consolidated fiscal year, we steadily advanced and expanded items in the development pipeline, focused on new drugs including “Tramset,” “Lexapro” and “Realda,” and pursued alliances related to the overseas expansion of “Epadel,” while continuing to invest in research and development and other activities for the future.」
With respect to research and development partnerships and strategic alliances, it is stated that alliances related to the overseas expansion of “Epadel” were steadily advanced. - FY2018-Q3RestatedAnnual report
「Our Group practices its corporate philosophy of “foresight, originality and research” and conducts research and development activities centered on prescription medicines while actively promoting research and development partnerships with companies in Japan and overseas.」
The policy of actively promoting research and development partnerships with companies in Japan and overseas is reaffirmed. New contracts related to sales are described separately as specific developments in partnerships inside and outside the Company. - FY2018-Q2RestatedAnnual report
「Our Group practices its corporate philosophy of “foresight, originality and research” and conducts research and development activities centered on prescription medicines while actively promoting research and development partnerships with companies in Japan and overseas.」
The policy of actively promoting research and development partnerships with companies in Japan and overseas is reaffirmed. - FY2018-Q1RestatedAnnual report
「Our Group practices its corporate philosophy of “foresight, originality and research” and conducts research and development activities centered on prescription medicines while actively promoting research and development partnerships with companies in Japan and overseas.」
The policy of actively promoting research and development partnerships with companies in Japan and overseas is reaffirmed. - FY2017-Q3RestatedAnnual report
「Our Group practices its corporate philosophy of “foresight, originality and research” and conducts research and development activities centered on prescription medicines while actively promoting research and development partnerships with companies in Japan and overseas.」
The policy of actively promoting research and development partnerships with companies in Japan and overseas is reaffirmed. - FY2017-Q2RestatedAnnual report
「Our Group practices its corporate philosophy of “foresight, originality and research” and conducts research and development activities centered on prescription medicines while actively promoting research and development partnerships with companies in Japan and overseas.」
The policy of actively promoting research and development partnerships with companies in Japan and overseas is reaffirmed. - FY2017-Q1RestatedAnnual report
「Our Group practices its corporate philosophy of “foresight, originality and research” and conducts research and development activities centered on prescription medicines while actively promoting research and development partnerships with companies in Japan and overseas.」
The policy of actively promoting research and development partnerships with companies in Japan and overseas is reaffirmed. - FY2016First statedAnnual report
「We will pursue strategic alliances that emphasize lifecycle management and partnerships.」
This was described as a means of achieving growth in the core pharmaceutical business.